Crescita TherapeuticsTSX:CTX 20 Gross Margin % is 46.90% as of Mar. 2026, which is 21% below its 10-year median of 59.02. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Crescita Therapeutics ranks better than 54.19% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Crescita Therapeutics had a gross margin of 46.90% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Crescita Therapeutics Gross Margin % Related Terms
Crescita Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Crescita Therapeutics (TSX:CTX) has a Gross Margin % of 46.90% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Crescita Therapeutics and its competitors. This is 21% below median its historical median of 59.02. Over the past decade, Crescita Therapeutics' Gross Margin % has ranged from 33.36 to 74.03. According to the industry distribution chart, Crescita Therapeutics ranks #432 out of 943 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is Crescita Therapeutics' Gross Margin % too high?
Crescita Therapeutics' current Gross Margin % of 46.90% is 21% below median its 10-year median of 59.02. Over the past 10 years, this metric has ranged from a low of 33.36 to a high of 74.03. The Drug Manufacturers industry median Gross Margin % is 48.54. Crescita Therapeutics' value of 46.90% is 3.4% below this industry median. Based on the distribution chart, Crescita Therapeutics ranks #432 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Crescita Therapeutics ranks #432 out of 943 companies for Gross Margin %. This puts Crescita Therapeutics in the upper half of its industry. The industry median Gross Margin % is 48.54. Crescita Therapeutics' value of 46.90% is 3.4% below this benchmark. Historically, Crescita Therapeutics' own Gross Margin % has ranged from 33.36 to 74.03 over the past decade. While the company's 10-year median is 59.02 vs. the industry median of 48.54, Crescita Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescita Therapeutics's current Gross Margin % of 46.90% is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Crescita Therapeutics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescita Therapeutics's current Gross Margin % is 46.90%, which is 21% below median its own 10-year median of 59.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Gross Margin % is 46.90%, which is 21% below median its 10-year median of 59.02 and 3.4% below the Drug Manufacturers industry median of 48.54. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Gross Margin % is 46.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued.
The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68.
GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:CTX:
Gross Margin %: 46.90% (21% below median its 10-year median of 59.02)
GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
Industry Position: 3.4% below the Drug Manufacturers median (#432 of 943)
No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
